New York, March 08, 2024 - PRISM MarketView - SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company focusing on treatments for central nervous system disorders, has recently initiated a clinical trial for autism spectrum disorder (ASD) by enrolling its first patient. The trial aims to assess the safety and effectiveness of SCI-210 in treating children aged between 5 and 18 years with ASD. This step represents an advance in the search for better treatments for ASD, a developmental disability that is estimated to affect about one in 36 children globally.
“Scientific innovation cannot forge ahead without patients that are willing to work with the scientific community by participating in clinical trials. The enrollment of our first patient means that we are moving towards a new frontier in the treatment of ASD. We are pleased to enroll the first patient in the trial, which will further our understanding of the potential role of SCI-210 in the treatment of ASD symptoms.”
Oz Adler, Chief Executive Officer of SciSparc
SPRC shares traded up 9% premarket following the news.
Highlights:
The clinical trial aims to assess SCI-210, a proprietary combination of cannabidiol (CBD) and CannAmide™, for its potential to alleviate symptoms of autism spectrum disorder in children.
SciSparc plans to enroll 60 participants aged between 5 and 18 for a 20-week double-blind, randomized, and placebo-controlled study. This study seeks to compare the effects of SCI-210 therapy to standard CBD treatment on ASD symptoms.
The trial will use three primary efficacy metrics: the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire, the Clinical Global Impressions-Improvement (CGI-I) scale, and the determination of an effective therapeutic dose.
SciSparc aims to first market SCI-210 in Israel, followed by other countries, contingent upon receiving necessary regulatory approvals.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on Amazon Marketplace.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)